EUVIMEDEUVIMED entdecken
Crossref

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Brendon L Neuen iD, Hiddo J L Heerspink iD, Priya Vart, Brian L Claggett iD, Robert A Fletcher iD, Clare Arnott iD, Julianna de Oliveira Costa iD, Michael O Falster iD, Sallie-Anne Pearson iD, Kenneth W Mahaffey iD, Bruce Neal iD, Rajiv Agarwal iD und 4 weitere

Circulation · 06.02.2024 · 149 (6) · 450-462

DOI: 10.1161/circulationaha.123.067584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 06.02.2024. Verfasst von Brendon L Neuen und 15 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 370-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. METHODS: We used data from 2 SGLT2i trials (CANVAS [Canagliflozin Cardiovascular Assessment] and CREDENCE [Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation]), 2 ns-MRA trials (FIDELIO-DKD [Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease] and FIGARO-DKD [Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease]), and 8 GLP-1 RA trials to estimate the relative effects of combination therapy versus conventional care (renin-angiotensin system blockade and traditional risk factor control) on cardiovascular, kidney, and mortality outcomes. Using actuarial methods, we then estimated absolute risk reductions with combination SGLT2i, GLP-1 RA, and ns-MRA in patients with type 2 diabetes and at least moderately increased albuminuria (urinary albumin:creatinine ratio ≥30 mg/g) by applying estimated combination treatment effects to participants receiving conventional care in CANVAS and CREDENCE. RESULTS: Compared with conventional care, the combination of SGLT2i, GLP-1 RA, and ns-MRA was associated with a hazard ratio of 0.65 (95% CI, 0.55–0.76) for major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death). The corresponding estimated absolute risk reduction over 3 years was 4.4% (95% CI, 3.0–5.7), with a number needed to treat of 23 (95% CI, 18–33). For a 50-year-old patient commencing combination therapy, estimated major adverse cardiovascular event–free survival was 21.1 years compared with 17.9 years for conventional care (3.2 years gained [95% CI, 2.1–4.3]). There were also projected gains in survival free from hospitalized heart failure (3.2 years [95% CI, 2.4–4.0]), chronic kidney disease progression (5.5 years [95% CI, 4.0–6.7]), cardiovascular death (2.2 years [95% CI, 1.2–3.0]), and all-cause death (2.4 years [95% CI, 1.4–3.4]). Attenuated but clinically relevant gains in event-free survival were observed in analyses assuming 50% additive effects of combination therapy, including for major adverse cardiovascular events (2.4 years [95% CI, 1.1–3.5]), chronic kidney disease progression (4.5 years [95% CI, 2.8–5.9]), and all-cause death (1.8 years [95% CI, 0.7–2.8]). CONCLUSIONS: In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment of SGLT2i, GLP-1 RA, and ns-MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesGlucagon-Like Peptide-1 Receptor AgonistsRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsHumansAlbuminuriaCanagliflozinKidneySurvival AnalysisRandomized Controlled Trials as TopicNaphthyridines

Stichwörter der Autor:innen

diabetes mellitus, type 2heart failuremortalityrenal insufficiency, chronictreatment outcome

Substanzen

CanagliflozinGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsfinerenoneNaphthyridines

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.N., B.L.C., S.D.S., M.V.).
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, The Netherlands (H.J.L.H., P.V.).
  • Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia (C.A.).
  • Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Australia (J.d.O.C., M.O.F., S.-A.P.).

ORCID-Profile: Brendon L Neuen, Hiddo J L Heerspink, Brian L Claggett, Robert A Fletcher, Clare Arnott, Julianna de Oliveira Costa, Michael O Falster, Sallie-Anne Pearson, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George Bakris, Vlado Perkovic, Scott D Solomon, Muthiah Vaduganathan

Zitieren

APA

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S. A., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G., Perkovic, V., Solomon, S. D., & Vaduganathan, M. (2024). Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation, 149(6), 450-462. https://doi.org/10.1161/circulationaha.123.067584

Vancouver

Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-462. doi:10.1161/circulationaha.123.067584

BibTeX
@article{Neuen2024,
  author = {Neuen, Brendon L and Heerspink, Hiddo J L and Vart, Priya and Claggett, Brian L and Fletcher, Robert A and Arnott, Clare and de Oliveira Costa, Julianna and Falster, Michael O and Pearson, Sallie-Anne and Mahaffey, Kenneth W and Neal, Bruce and Agarwal, Rajiv and Bakris, George and Perkovic, Vlado and Solomon, Scott D and Vaduganathan, Muthiah},
  title = {Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {6},
  pages = {450--462},
  doi = {10.1161/circulationaha.123.067584}
}
Kostenlos starten →